Idera Pharmaceuticals Inc (NASDAQ:IDRA) is reporting translational data supporting the mechanism of action of intratumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist from …
In a research report sent to investors today, Cowen analyst Boris Peaker maintained an Outperform rating on Idera (NASDAQ:IDRA), while no price target …
